Vonoprazan Versus Conventional Proton Pump Inhibitor in the Therapeutic Armamentarium of Peptic Ulcer Disease and Gastroesophageal Reflux Disease
Vonoprazan is a novel potassium-competitive acid blocker that has been introduced as an effective treatment option in peptic ulcer and gastroesophageal reflux diseases. Its adverse events panel is encouraging compared to standard proton pump inhibitors, although higher hypergastrinemia and foveolar-...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2021
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/79429 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Vonoprazan is a novel potassium-competitive acid blocker that has been introduced as an effective treatment option in peptic ulcer and gastroesophageal reflux diseases. Its adverse events panel is encouraging compared to standard proton pump inhibitors, although higher hypergastrinemia and foveolar-type gastric adenocarcinoma occurrence have been described. The efficiency is proved in gastric and duodenal ulcer, gastroesophageal reflux and gastric post- endoscopic submucosal dissection ulcers, with higher ulcer shrinkage rate and no incremental risk for bleeding. The new therapies containing Vonoprazan instead of convention proton pump inhibitors against Helicobacter pylori are safe and well-tolerated, being associated with a better eradication rate. However, the therapy should be adjusted to the body size. |
|---|---|
| ISBN: | 978-1-83968-419-7 |
| DOI: | 10.5772/intechopen.101349 |